Placebo-controlled trial of prednisone in advanced HIV-1 infection

AIDS

Volumn 15, Issue 3, 2001, Pages 321-327

  McComsey, Grace A ^a,d   Whalen, Christopher C ^a   Mawhorter, Steven D ^b   Asaad, Robert ^a   Valdez, Hernan ^a   Patki, Abhay H ^a   Klaumunzner, Jared ^a   Gopalakrishna, Kuttetoor V ^c   Calabrese, Leonard H ^b   Lederman, Michael M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c FAIRVIEW HOSPITAL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

AIDS; Corticosteroids; Cytokines; HIV 1 infection; Immune activation; Immune based therapy; Tumor necrosis factor

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; PREDNISONE; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LEUKOCYTE COUNT; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTERLEUKIN-6; MALE; PLACEBOS; PREDNISONE; RNA; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 0035895656     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200102160-00004     Document Type: Article

References (32)

1. The prognostic value of cellular and serologic markers in HIV infection
2. T cell activation and disease severity in HIV infection
3. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study
4. High-dose pentoxifylline in patients with AIDS: Inhibition of tumor necrosis factor production
5. Sustained increases in CD4 cell counts in asymptomatic HIV-1-positive patients treated with prednisolone for 1 year
6. Immunologic and virologic effects of glucocorticoids on human immunodeficiency virus infection in children: A preliminary study
7. Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss
8. CD4+ T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type-1-infected subjects
9. HIV infection perturbs DNA content of lymphoid cells: Partial correction after 'suppression' of virus replication
10. Random-effects models for longitudinal data
11. Steroid-induced Kaposi's sarcoma in a patient with pre-AIDS
12. Treatment with corticosteroids - A risk factor for the development of clinical cytomegalovirus disease in AIDS
13. Possible risk of steroid administration in patients at risk for AIDS
14. Prednisone improves renal function and proteinuria in HIV-associated nephropathy
15. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy
16. Complications of corticosteroid therapy in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia
17. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS)
18. Tumor necrosis factor and interleukin 1 stimulate the human immuodeficiency virus enhancer by activation of the nuclear factor B
19. Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to NFκB sites in the long terminal repeat
20. Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor-α
21. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of iκB synthesis
22. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
23. Influence of tuberculosis on human immunodeficiency virus (HIV): Enhanced cytokine expression and elevated beta 2-microglobulin in HIVassociated tuberculosis
24. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage
25. Modeling the relationships among HIV-1 replication, immune activation and CD4+ T cell losses using adjusted correlative analyses
26. Effects of prednisone on human immunodeficiency virus infection
27. Increased immune activation markers precedes the inflection point of CD4 T cells and the increased serum virus load in HIV infection
28. Molecular regulation of apoptosis: Genetic controls on cell death
29. + T cells from HIVinfected asymptomatic individuals
30. Programmed death of T cells in HIV infection: No correlation with progression to disease
31. + T lymphocytes from activation-induced apoptosis triggered by HIV-1: Implications for pathogenesis and therapy
32. Glucocorticoids potently block tumour necrosis factor-alpha- and lipopolysaccharide-induced apoptotic cell death in bovine glomerular endothelial cells upstream of caspase 3 activation